Anti CD69SKU: P-81

General description: 

Monoclonal Mouse

Anti-Human CD69, Clone FN50

CD69 is a phosphorylated disulphide-linked dimer composed of two chains of 26 to 28 kDa and 32 to 34 kDa, also known as Activation Inducer Molecule (AIM). CD69 is the earliest known surface antigen expressed on lymphocytes after T or B cell activation but absent from resting lymphocytes. Other cells, including activated macrophages, natural killer (NK) cells, eosinophils, neutrophils and platelets may also express CD69. In vitro studies have demonstrated a transient expression of CD69 on activated T cells. After activation, surface expression can be detected within 2-4 hours, reaching a maximum after 18-24 hours followed by a rapid decrease. CD69 is thus detectable prior to other activation antigens like CD25 and CD71. CD69 is believed to be involved in signal transduction, since cross-linking with anti-CD69 antibodies induce activation.In combination with anti-CD4, anti-CD8, and anti-CD3 antibodies, anti-CD69 may be useful for T cell activation studies.

References: 

Beiske K, AAS-Eng DA, Smeland EB, Sundan A, Marton PF, Funderud S. A4.2 Immunohistological and functional characterization of the mAb A91 (FN 50)-reactive activation antigen (CD69) expressed on subsets of normal and neoplastic lymphoid cells. In Knapp W et al., eds. Leucocyte Typing IV. White Cell Differentiation Antigens. Oxford-New York-Tokyo: Oxford University Press, 1989:436-9.

Cebrián M, Sánchez-Mateos P, Redondo JM, Ursa A, De Landázuri MO, Sánchez-Madrid F. A4.4 CD69:a GP33/27 kDa activation inducer molecule (AIM) recognized by a group of mAb of the workshop activation panel. Induction of T-cell proliferation through the AIM activation antigen. In Knapp W et al., eds. Leucocyte Typing IV. White Cell Differentiation Antigens. Oxford-New York-Tokyo: Oxford University Press, 1989:441-4.

Hamann J, Fiebig H, Strauss M. AA4.1 Expression cloning and chromosomal sublocalization of the early activation antigen CD69. In: Schlossman SF et al., eds. Leucocyte Typing V. White Cell Differentiation Antigens. Oxford-New York-Tokyo: Oxford University Press, 1995:1125-6.

 

About the scientist

June Helen Myklebust

co-PI, Senior scientist, PhD

The main focus of our research is to study B-cell lymphoma biology, and we perform molecular characterization as well as functional studies. Lymphomas are cancers derived from the cells of the immune system, and most often they arise from B-cells in the lymph nodes. By the means of high throughput analysis of gene expression and genomic and epigenetic alterations in lymphoma samples, we aim to elucidate oncogenetic mechanisms in lymphoma development. We also aim to identify prognostic markers and characterize biologically different subgroups of lymphoma.

We have a strong translational focus with a close collaboration with the lymphoma program in the Hospital and an extensive international collaboration. Several projects are connected to ongoing clinical trials, and we analyze primary patient samples using a broad spectrum of methods.

Selected lymphoma-specific genetic aberrations are followed up by basic cell biology research, using B cell lymphoma cell lines as models. Central techniques include studies of signalling pathways by Western blot analysis and multicolour flow cytometry, confocal microscopy, tissue micro array (TMA), array copy number genetic changes (aCGH), and gene expression profiling.  
 

Group leader: Erlend Bremertun Smeland, PI, MD/PhD

http://ous-research.no/ebsmeland/